Abstract:Abstract Platelets play a crucial role in hemostasis. For cardiovascular and stroke prophylaxis, patients are commonly placed on either single or dual antiplatelet drugs, such as aspirin and/or clopidogrel. Here we outline a mouse model examining antiplatelet therapy and the resulting changes in platelet activation and aggregation. Using commercially available transgenic mice with platelets expressing green fluorescent protein (GFP) or red fluorescent protein (RFP), endogenous platelets were inhibited with a single, dual, or control antiplatelet treatment. We used 100μg aspirin/g mouse or 50μg clopidogrel/g mouse for a single dose; dual antiplatelet therapy was a combined dose of 100μg aspirin/g mouse and 50μg clopidogrel/g; control treatment was DMSO alone. One hour after treatment, whole blood (WB) was collected by aseptic cardiac puncture and mixed in the following groups: aspirin treated RFP and GFP WB, clopidogrel treated RFP and GFP WB, aspirin and clopidogrel treated RFP and GFP WB, control treated RFP and GFP WB. Each combined sample was then treated with a panel of agonists: no agonist, 0.5U/mL thrombin, 20μM ADP, and 500μg/mL arachidonic acid. Thrombin samples were activated for 2 minutes at room temperature while ADP and arachidonic acid samples were activated for 10 minutes at 37°C. Platelets were labeled with anti-CD41a to label all platelets and anti-CD62P to label activated platelets. Aggregation is measured as double-colored GFP and RFP platelet events. Compared to control mice, mice treated with antiplatelet agents demonstrated statistically significant decreases in activation following thrombin administration (ranging from 90% to 83% activated); there was no significant difference in platelet aggregation following thrombin among the samples from different antiplatelet therapies. Following ADP activation, clopidogrel treatment decreased platelet activation (1% activation) compared to control (3% activation) and aspirin-treated (5% activation) mice with no additional decrease in dual treatment (1% activation); unexpectedly, aspirin treatment alone or dual therapy decreased platelet aggregation with ADP (15% and 17% aggregated, respectively) compared to control and clopidogrel (23% and 27% aggregated, respectively). Finally, after arachidonic acid activation, aspirin treatment significantly decreased activation (7% activated) compared to control (20% activated), while clopidogrel decreased activation more than that of aspirin (3% activated), with no additional decrease from dual therapy (3% activated). Though not significant, aspirin treatment (1.4% aggregation) and dual therapy (1.2%) demonstrated a trend with decreased platelet aggregation following arachidonic acid activation compared to control (1.8% aggregation) and clopidogrel-treated platelets (3.2%). These data presented here show a novel application of platelet activation and aggregation of GFP and RFP platelet populations in a mouse model following aspirin and/or clopidogrel treatment. This model can be applied generally to other drugs and disease models for platelet dysfunction using additional markers for platelet activation. Additionally, these experiments can be used to further investigate the function of transfused murine platelets.

Statin therapy in heart failure: is it time for a second look?

Factors that modulate platelet reactivity as measured by 5 assay platforms in 3429 individuals

The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count

Feasibility and comparability of different platelet function tests in acute stroke with or without prior antiplatelet therapy

Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study

The Conductivity of Disposable Plastic Circuits

Quantifying the effect of antiplatelet therapy by whole blood platelet aggregometry

The differential formation and composition of leukocyte-platelet aggregates induced by various cellular stimulants

Effect of ADC non-ideal characteristics on GNSS antenna array anti-jamming

A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy

Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]

Optimized Methodology to Produce Platelet-Rich Plasma and Perform Platelet Aggregation in Patients With Coronary Artery Disease

The Upper CambrianRehbachiella, its larval development, morphology and significance for the phylogeny of Branchiopoda and Crustacea

Study of the Association of PEAR1, P2Y12, and UGT2A1 Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients.

Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement

Physiological platelet aggregation assay to mitigate drug-induced thrombocytopenia using a microphysiological system

Platelet Aggregability as a Predictor of Restenosis Following Carotid Endarterectomy

Using an agonist panel and aggregation to assess antiplatelet therapy in mice

Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser

Platelet Aggregation in Direct Oral Factor Xa Inhibitors–treated Patients With Atrial Fibrillation: A Pilot Study

The Effect of 4-Methylcatechol on Platelets in Familial Hypercholesterolemic Patients Treated with Lipid Apheresis and/or Proprotein Convertase Subtilisin Kexin 9 Monoclonal Antibodies